ClinicalTrials.gg
Active, not recruitingNCT06792695CANTORUpdated Oct 22, 2026

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

A Phase 2 interventional study of Volrustomig and FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) in Metastatic Colorectal Cancer, sponsored by AstraZeneca. Active, not recruiting at 56 sites in 12 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Updated Oct 22, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Colorectal Neoplasms by AstraZeneca — 2 open to participants now, 8 under way, none of them phase 3. Colorectal Neoplasms · AstraZeneca.

Enrollment
13th of 28
82 · median 69
Started
2025
with 1 other
Phase 2
12 of 29
1 open now
Registered
28th of 29
by date

Among the 29 studies in Colorectal Neoplasms by AstraZeneca, this one is the 13th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 in phase 2, and was the 28th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

2 of the 29 studies in Colorectal Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Colorectal Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Read the detailed description

This is a Phase II, platform, open-label, multi-drug, multicenter, global study.

This is a modular study, that includes a master protocol and substudies.

Partcipants will be randomised to one of the following intervention groups:

  • Volrustomig + FOLFIRI + bevacizumab group (Arm A)
  • FOLFIRI + bevacizumab group (Arm B)

The substudy will evaluate the effects of volrustomig in combination with FOLFIRI (irinotecan, 5-FU, and leucovorin) and bevacizumab versus FOLFIRI and bevacizumab only in participants with Mismatch-repair-proficient (pMMR)/Microsatellite stable (MSS) metastatic CRC (mCRC) in the absence of liver metastases and who have not received previous systemic treatment for advanced or metastatic disease.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Metastatic disease
  • Immunotherapy
  • Liver metastasis
  • Mismatch-repair-proficient
  • Antibody targeting
  • Colorectal Cancer
  • CANTOR
04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Overall Inclusion Criteria:

  • Histopathologically confirmed colorectal adenocarcinoma.
  • Provision of FFPE tumor sample collected as per SoC.
  • Presence of by 1.1 criteria.
  • performance status of 0 or 1.
  • ≥ 12 weeks at the time of screening.

Substudy Inclusion Criteria:

  • No radiological evidence of liver .
  • No prior systemic therapy for mCRC, prior /adjuvant chemotherapy is permitted only when given for resected (M0) disease and only after at least 6 months have elapsed since completion of that therapy and diagnosis of recurrent or metastatic disease.
  • Known pMMR/MSS status (only pMMR/MSS mCRC allowed).
  • Adequate organ and bone marrow function
  • Body weight > 35 kg at screening and at randomization.
  • use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Overall Exclusion Criteria:

  • Central nervous system metastases or spinal cord compression
  • Known history of severe allergy to any monoclonal antibody or study intervention.
  • Any unresolved toxicity Grade ≥ 2 from a previous anticancer therapy.
  • History of another primary .

Substudy Exclusion Criteria:

  • Potentially resectable disease with multidisciplinary plan for radical surgery.
  • Active or prior documented or inflammatory disorders or cardiac conditions.
  • Participants with a prior history of hypertensive crisis or hypertensive encephalopathy or bleeding risks.
  • Deep venous thrombosis, pulmonary embolism, arterial thrombosis, or cerebrovascular accident.
  • History of abdominal or tracheoesophageal fistula, GI perforation and/or fistulae, or intraabdominal abscess within 6 months prior to randomization.
  • Prior exposure to immune mediated therapy.
  • History of active primary immunodeficiency.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Volrustomig + FOLFIRI+ Bevacizumab group (Arm A)

    Participants will receive FOLFIRI and bevacizumab together with volrustomig.

    Drug: Volrustomig · Drug: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) · Drug: Bevacizumab

  • Active comparator
    FOLFIRI+ BEVACIZUMAB group (Arm B)

    Partcipants will receive FOLFIRI and bevacizumab.

    Drug: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) · Drug: Bevacizumab

Interventions

  • Volrustomig will be administered as intravenous (IV) infusion.

    Also known as: MEDI5752

  • DrugFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)

    FOLFIRI will be administered as IV infusion.

  • Bevacizumab will be administered as IV infusion.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization until progression per Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST 1.1) or death due to any cause.

    Time frame: Approximately 3 years

  2. Number of Participants with Adverse Events (AEs)

    Number of participants who received at least one dose of study treatment will be assessed.

    Time frame: Approximately 3 years

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization until the date of death due to any cause.

    Time frame: Approximately 3 years

  2. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have a confirmed complete response or confirmed partial response as per RECIST 1.1.

    Time frame: Approximately 3 years

  3. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who have a confirmed CR or PR or who have SD per RECIST 1.1 after randomization.

    Time frame: Approximately 3 years

  4. Duration of Response (DOR)

    DoR is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 or death due to any cause.

    Time frame: Approximately 3 years

  5. Time to second progression or death (PFS2)

    PFS2 is defined as the time from randomization to the earliest of the progression event, after first subsequent therapy, or death.

    Time frame: Approximately 3 years

  6. Maximum Observed Concentration (Cmax)

    Concentration of novel study intervention in serum and PK parameters as data allow (such as peak and trough concentrations) will be assessed.

    Time frame: Approximately 3 years

  7. Observed lowest concentration before the next dose is administered (Ctrough)

    Concentration of novel study intervention in serum and PK parameters as data allow (such as peak and trough concentrations) will be assessed.

    Time frame: Approximately 3 years

  8. Number of patients with positive Antidrug Antibodies (ADAs)

    The immunogenicity (ADAs) of novel study intervention in participants with CRC in the absence of liver metastases is investigated.

    Time frame: Approximately 3 years

07

Study locations

56 sites
  • Research Site
    Scottsdale, Arizona 85259, United States
  • Research Site
    Los Angeles, California 90089, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Trenton, New Jersey 08690, United States
  • Research Site
    Rochester, New York 14618, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    East Melbourne, 3002, Australia
  • Research Site
    Wollongong, 2500, Australia
  • Research Site
    Woodville South, 5011, Australia
  • Research Site
    Victoria, British Columbia V8R 6V5, Canada
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
  • Research Site
    Toronto, Ontario M5G 1X6, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Beijing, 100142, China
  • Research Site
    Montpellier, 34090, France
  • Research Site
    Poitiers, 86021, France
  • Research Site
    Saint-Priez En Jarez, 42270, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Hamburg, 22763, Germany
  • Research Site
    Marburg, 35043, Germany
  • Research Site
    Bologna, 40133, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Amsterdam, 1066 CX, Netherlands
  • Research Site
    Maastricht, 6202 AZ, Netherlands
  • Research Site
    Zwolle, 8025 AB, Netherlands
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Seoul, 06591, South Korea
  • Research Site
    Seoul, 5505, South Korea
  • Research Site
    Yongin-si, 16995, South Korea
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 8003, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Pamplona, 31005, Spain
  • Research Site
    Santander, 39008, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Kaohsiung City, 80756, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Yung Kang City, 71044, Taiwan
  • Research Site
    Cambridge, CB2 0XY, United Kingdom
  • Research Site
    London, NW1 2PG, United Kingdom
  • Research Site
    London, W12 0HS, United Kingdom
  • Research Site
    Manchester, M20 4GJ, United Kingdom
  • Research Site
    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes",indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2027, 27 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 27 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 27, 2025
StartActual
Mar 12, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Sep 29, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 22, 2026
Sites
20 sites removed
Show 20 removed
  • Research Site · Chicago, United States
  • Research Site · Cleveland, United States
  • Research Site · Portland, United States
  • Research Site · Philadelphia, United States
  • Research Site · Chengdu, China
  • Research Site · Harbin, China
  • Research Site · Shanghai, China
  • Research Site · Shanghai, China
  • Research Site · Shanghai, China
  • Research Site · Wuhan, China
  • Research Site · Zhengzhou, China
  • Research Site · Bordeaux, France
  • Research Site · Marseille, France
  • Research Site · Montpellier, France
  • Research Site · Castelfranco Veneto, Italy
  • Research Site · Milan, Italy
  • Research Site · Pavia, Italy
  • Research Site · Pisa, Italy
  • Research Site · Roma, Italy
  • Research Site · Madrid, Spain
Oct 22, 2026
Enrollment
80 (estimated)→82 (actual)
Oct 22, 2026
Eligibility
1 criterion edited, 1 added
What changed in the criteria
  • EditedNo prior systemic therapy for mCRC, except forprior neoadjuvant/adjuvant chemotherapy where, >is permitted only when given for resected (M0) disease and only after at least 6 months have elapsed betweensince completion of that therapy and documented date of diagnosis of recurrent or metastatic disease.
  • AddedHistory of active primary immunodeficiency.
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Recruiting→Active, not recruiting
    20 sites removed
    Show 20 removed
    • Research Site · Chicago, United States
    • Research Site · Cleveland, United States
    • Research Site · Portland, United States
    • Research Site · Philadelphia, United States
    • Research Site · Chengdu, China
    • Research Site · Harbin, China
    • Research Site · Shanghai, China
    • Research Site · Shanghai, China
    • Research Site · Shanghai, China
    • Research Site · Wuhan, China
    • Research Site · Zhengzhou, China
    • Research Site · Bordeaux, France
    • Research Site · Marseille, France
    • Research Site · Montpellier, France
    • Research Site · Castelfranco Veneto, Italy
    • Research Site · Milan, Italy
    • Research Site · Pavia, Italy
    • Research Site · Pisa, Italy
    • Research Site · Roma, Italy
    • Research Site · Madrid, Spain
    Enrollment 80 (estimated)→82 (actual)
    Eligibility 1 criterion edited, 1 added
    What changed in the criteria
    • EditedNo prior systemic therapy for mCRC, except forprior neoadjuvant/adjuvant chemotherapy where, >is permitted only when given for resected (M0) disease and only after at least 6 months have elapsed betweensince completion of that therapy and documented date of diagnosis of recurrent or metastatic disease.
    • AddedHistory of active primary immunodeficiency.
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06792695
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Mar 12, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Sep 29, 2028 (estimated)
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Volrustomig

Start the discussion